SCHEMBL1074091

SCHEMBL1074091

O=C(Nc1ccccc1)N1CCN(c2ccc3cc2CCc2cccc(c2)Nc2ncc(Cl)c(n2)N3)CC1

nearest known ligand 0.72

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 10/20 0.72
GOT1 P17174 2/20 0.42
TRPV1 Q8NER1 3/20 0.41
P2RY12 Q9H244 1/20 0.41
STK4 Q13043 1/20 0.41
STK3 Q13188 1/20 0.41
STK26 Q9P289 1/20 0.41
STK24 Q9Y6E0 1/20 0.41
JAK2 O60674 4/20 0.41
JAK1 P23458 4/20 0.41
TYK2 P29597 4/20 0.41
JAK3 P52333 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4371092 0.96 ALK (0.66) ALKGOT1TRPV1P2RY12STK4
SCHEMBL1076850 0.92 ALK (0.67) ALKGOT1TRPV1STK4STK3
SCHEMBL1076611 0.92 ALK (0.67) ALKGOT1TRPV1
SCHEMBL1074023 0.91 ALK (0.66) ALKTRPV1STK4STK3STK26
Trifluoroacetic Acid SCHEMBL4363168 0.91 ALK (0.63) ALKGOT1TRPV1
SCHEMBL1076871 0.90 ALK (0.65) ALKGOT1TRPV1
Trifluoroacetic Acid SCHEMBL4360466 0.89 ALK (0.61) ALKGOT1TRPV1
Trifluoroacetic Acid SCHEMBL4360985 0.89 ALK (0.61) ALKGOT1TRPV1P2RY12STK4
Trifluoroacetic Acid SCHEMBL4360146 0.88 ALK (0.60) ALKP2RY12
SCHEMBL1073235 0.88 ALK (0.75) ALKSTK4STK3STK26STK24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US claimed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US claimed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO claimed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885GOT1 664/4885TRPV1 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.